Trevitha Therapeutics

Trevitha Therapeutics is a London-based biotechnology company focused on the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company utilizes a proprietary platform to design small molecules that recruit the body's natural cellular machinery to eliminate disease-causing proteins, particularly those deemed "undruggable" by conventional methods. Led by CEO Ian Churcher, a pioneer in the TPD field, Trevitha aims to create highly potent and selective degraders for applications in oncology and inflammatory diseases. The firm operates at the intersection of advanced structural biology and medicinal chemistry to optimize the degradation of specific protein targets.